Brain,
Journal Year:
2024,
Volume and Issue:
147(10), P. 3325 - 3343
Published: July 11, 2024
Concomitant
Alzheimer's
disease
(AD)
pathology
is
a
frequent
event
in
the
context
of
Lewy
body
(LBD),
occurring
approximately
half
all
cases.
Evidence
shows
that
LBD
patients
with
AD
copathology
show
an
accelerated
course,
greater
risk
cognitive
decline
and
overall
poorer
prognosis.
However,
LBD-AD
cases
may
heterogeneous
motor
non-motor
phenotypes
higher
dementia
and,
consequently,
be
not
rarely
misdiagnosed.
In
this
review,
we
summarize
current
understanding
by
discussing
synergistic
effects
neuropathological
changes
their
clinical
relevance.
Furthermore,
provide
extensive
overview
neuroimaging
fluid
biomarkers
under
assessment
for
use
possible
diagnostic
prognostic
values.
can
predicted
vivo
means
CSF,
MRI
PET
markers,
whereas
most
promising
technique
to
date
identifying
different
biological
tissues
α-synuclein
seed
amplification
assay.
Pathological
imaging
CSF
are
associated
likelihood
but
do
always
mirror
severity
as
pure
AD.
Implementing
blood-based
might
allow
faster
screening
copathology,
thus
improving
sensitivity
LBD-AD.
Finally,
discuss
literature
on
novel
candidate
being
exploited
investigate
other
aspects
neurodegeneration,
such
neuroaxonal
injury,
glial
activation
synaptic
dysfunction.
The
thorough
characterization
should
taken
into
account
when
considering
differential
diagnoses
syndromes,
evaluation
individual
level,
guide
symptomatic
disease-modifying
therapies.
npj Parkinson s Disease,
Journal Year:
2024,
Volume and Issue:
10(1)
Published: March 1, 2024
Abstract
Parkinson’s
disease
(PD)
is
a
heterogeneous
movement
disorder
with
different
motor
subtypes
including
tremor
dominant
(TD),
indeterminate
and
postural
instability,
gait
disturbance
(PIGD)
subtypes.
Plasma
glial
fibrillary
acidic
protein
(GFAP)
was
elevated
in
PD
patients
may
be
regarded
as
biomarker
for
cognitive
progression.
Here
we
explore
if
there
an
association
between
plasma
GFAP
whether
baseline
level
can
predict
subtype
conversion.
Patients
classified
TD,
PIGD
or
underwent
neurological
evaluation
at
2
years
follow-up.
controls
were
measured
using
ultrasensitive
single
molecule
array.
The
study
enrolled
184
95
control
subjects.
levels
significantly
higher
the
group
compared
to
TD
2-year
Finally,
45%
of
had
shift
85%
remained
Baseline
converted
than
non-converters
group.
Higher
associated
conversion
(
OR
=
1.283,
P
0.033)
lower
likely
0.551,
0.021)
after
adjusting
confounders.
serve
clinical
utility
differentiating
predicting
patients.
Nature Aging,
Journal Year:
2024,
Volume and Issue:
4(11), P. 1529 - 1537
Published: Nov. 12, 2024
Abstract
Recently
approved
anti-amyloid
immunotherapies
for
Alzheimer’s
disease
(AD)
require
evidence
of
amyloid-β
pathology
from
positron
emission
tomography
(PET)
or
cerebrospinal
fluid
(CSF)
before
initiating
treatment.
Blood-based
biomarkers
promise
to
reduce
the
need
PET
CSF
testing;
however,
their
interpretation
at
individual
level
and
circumstances
requiring
confirmatory
testing
are
poorly
understood.
Individual-level
diagnostic
test
results
requires
knowledge
prevalence
in
relation
clinical
presentation
(clinical
pretest
probability).
Here,
a
study
6,896
individuals
evaluated
11
cohort
studies
six
countries,
we
determined
positive
negative
predictive
value
five
plasma
cognitively
impaired
probability.
We
observed
that
p-tau217
could
rule
with
probable
AD
dementia
(positive
above
95%).
In
mild
cognitive
impairment,
depended
on
patient
age.
Negative
out
non-AD
syndromes
(negative
between
90%
99%).
Our
findings
provide
framework
individual-level
biomarkers,
suggesting
combined
phenotyping
can
identify
patients
where
be
ruled
without
testing.
Brain,
Journal Year:
2024,
Volume and Issue:
147(10), P. 3325 - 3343
Published: July 11, 2024
Concomitant
Alzheimer's
disease
(AD)
pathology
is
a
frequent
event
in
the
context
of
Lewy
body
(LBD),
occurring
approximately
half
all
cases.
Evidence
shows
that
LBD
patients
with
AD
copathology
show
an
accelerated
course,
greater
risk
cognitive
decline
and
overall
poorer
prognosis.
However,
LBD-AD
cases
may
heterogeneous
motor
non-motor
phenotypes
higher
dementia
and,
consequently,
be
not
rarely
misdiagnosed.
In
this
review,
we
summarize
current
understanding
by
discussing
synergistic
effects
neuropathological
changes
their
clinical
relevance.
Furthermore,
provide
extensive
overview
neuroimaging
fluid
biomarkers
under
assessment
for
use
possible
diagnostic
prognostic
values.
can
predicted
vivo
means
CSF,
MRI
PET
markers,
whereas
most
promising
technique
to
date
identifying
different
biological
tissues
α-synuclein
seed
amplification
assay.
Pathological
imaging
CSF
are
associated
likelihood
but
do
always
mirror
severity
as
pure
AD.
Implementing
blood-based
might
allow
faster
screening
copathology,
thus
improving
sensitivity
LBD-AD.
Finally,
discuss
literature
on
novel
candidate
being
exploited
investigate
other
aspects
neurodegeneration,
such
neuroaxonal
injury,
glial
activation
synaptic
dysfunction.
The
thorough
characterization
should
taken
into
account
when
considering
differential
diagnoses
syndromes,
evaluation
individual
level,
guide
symptomatic
disease-modifying
therapies.
